(HIMS) Hims Hers Health - Overview
Stock: Telehealth, Prescription, Skincare, Haircare, Wellness
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 65.7% |
| Relative Tail Risk | -10.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.05 |
| Alpha | -74.33 |
| Character TTM | |
|---|---|
| Beta | 2.146 |
| Beta Downside | 2.489 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.51% |
| CAGR/Max DD | 0.51 |
Description: HIMS Hims Hers Health January 04, 2026
Hims & Hers Health, Inc. (NYSE:HIMS) runs a telehealth platform that links U.S., U.K., Canadian, and other international consumers with licensed clinicians, delivering both prescription and over-the-counter health and wellness products through its website and mobile app. Its catalog spans general wellness (e.g., melatonin, biotin), skincare (moisturizers, serums), sexual health (condoms, delay sprays, vibrators), and hair care (shampoos, minoxidil), while also offering recurring prescription fulfillment, post-consultation support, and a lab-based monitoring service that generates doctor-crafted action plans.
Recent data shows HIMS generated approximately $560 million in revenue for FY 2023, with subscription-based prescriptions growing at a 35% year-over-year rate-a key driver of recurring cash flow. The broader telehealth market is expanding at a compound annual growth rate of roughly 22% through 2028, propelled by shifting consumer preferences toward digital care and favorable reimbursement policies. Additionally, the company’s wholesale partnerships now account for about 12% of total sales, diversifying its distribution channels beyond direct-to-consumer.
For a deeper, data-driven look at HIMS’s valuation and risk profile, consider reviewing the analysis available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 133.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -18.95 > 1.0 |
| NWC/Revenue: 17.84% < 20% (prev 13.99%; Δ 3.85% < -1%) |
| CFO/TA 0.15 > 3% & CFO 325.1m > Net Income 133.8m |
| Net Debt (772.2m) to EBITDA (157.9m): 4.89 < 3 |
| Current Ratio: 1.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (248.7m) vs 12m ago 5.79% < -2% |
| Gross Margin: 75.01% > 18% (prev 0.81%; Δ 7420 % > 0.5%) |
| Asset Turnover: 155.9% > 50% (prev 206.2%; Δ -50.28% > 0%) |
| Interest Coverage Ratio: -9.29 > 6 (EBITDA TTM 157.9m / Interest Expense TTM -12.4m) |
Altman Z'' 1.42
| A: 0.18 (Total Current Assets 845.3m - Total Current Liabilities 450.8m) / Total Assets 2.23b |
| B: -0.06 (Retained Earnings -134.4m / Total Assets 2.23b) |
| C: 0.08 (EBIT TTM 115.4m / Avg Total Assets 1.42b) |
| D: -0.08 (Book Value of Equity -133.4m / Total Liabilities 1.65b) |
| Altman-Z'' Score: 1.42 = BB |
Beneish M 1.00
| DSRI: 5.08 (Receivables 41.3m/4.57m, Revenue 2.21b/1.24b) |
| GMI: 1.08 (GM 75.01% / 81.13%) |
| AQI: 1.24 (AQ_t 0.44 / AQ_t-1 0.35) |
| SGI: 1.78 (Revenue 2.21b / 1.24b) |
| TATA: -0.09 (NI 133.8m - CFO 325.1m) / TA 2.23b) |
| Beneish M-Score: 1.02 (Cap -4..+1) = D |
What is the price of HIMS shares?
Over the past week, the price has changed by -15.02%, over one month by -35.08%, over three months by -44.56% and over the past year by -43.12%.
Is HIMS a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 6
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the HIMS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 41.6 | 80.8% |
| Analysts Target Price | 41.6 | 80.8% |
| ValueRay Target Price | 24.7 | 7.2% |
HIMS Fundamental Data Overview January 31, 2026
P/E Forward = 43.4783
P/S = 3.0755
P/B = 11.2339
P/EG = 1.5739
Revenue TTM = 2.21b USD
EBIT TTM = 115.4m USD
EBITDA TTM = 157.9m USD
Long Term Debt = 971.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.42m USD (from shortTermDebt, last quarter)
Debt = 1.12b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 772.2m USD (from netDebt column, last quarter)
Enterprise Value = 7.29b USD (6.80b + Debt 1.12b - CCE 629.7m)
Interest Coverage Ratio = -9.29 (Ebit TTM 115.4m / Interest Expense TTM -12.4m)
EV/FCF = 55.41x (Enterprise Value 7.29b / FCF TTM 131.5m)
FCF Yield = 1.80% (FCF TTM 131.5m / Enterprise Value 7.29b)
FCF Margin = 5.95% (FCF TTM 131.5m / Revenue TTM 2.21b)
Net Margin = 6.05% (Net Income TTM 133.8m / Revenue TTM 2.21b)
Gross Margin = 75.01% ((Revenue TTM 2.21b - Cost of Revenue TTM 552.5m) / Revenue TTM)
Gross Margin QoQ = 73.80% (prev 76.39%)
Tobins Q-Ratio = 3.26 (Enterprise Value 7.29b / Total Assets 2.23b)
Interest Expense / Debt = 0.14% (Interest Expense 1.58m / Debt 1.12b)
Taxrate = 29.05% (3.55m / 12.2m)
NOPAT = 81.9m (EBIT 115.4m * (1 - 29.05%))
Current Ratio = 1.88 (Total Current Assets 845.3m / Total Current Liabilities 450.8m)
Debt / Equity = 1.92 (Debt 1.12b / totalStockholderEquity, last quarter 581.0m)
Debt / EBITDA = 4.89 (Net Debt 772.2m / EBITDA 157.9m)
Debt / FCF = 5.87 (Net Debt 772.2m / FCF TTM 131.5m)
Total Stockholder Equity = 542.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.44% (Net Income 133.8m / Total Assets 2.23b)
RoE = 24.67% (Net Income TTM 133.8m / Total Stockholder Equity 542.4m)
RoCE = 7.63% (EBIT 115.4m / Capital Employed (Equity 542.4m + L.T.Debt 971.0m))
RoIC = 7.97% (NOPAT 81.9m / Invested Capital 1.03b)
WACC = 11.88% (E(6.80b)/V(7.92b) * Re(13.82%) + D(1.12b)/V(7.92b) * Rd(0.14%) * (1-Tc(0.29)))
Discount Rate = 13.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.89%
[DCF Debug] Terminal Value 62.80% ; FCFF base≈138.8m ; Y1≈123.9m ; Y5≈104.6m
Fair Price DCF = 1.44 (EV 1.09b - Net Debt 772.2m = Equity 316.4m / Shares 219.3m; r=11.88% [WACC]; 5y FCF grow -13.20% → 2.90% )
EPS Correlation: 69.45 | EPS CAGR: 45.46% | SUE: -0.46 | # QB: 0
Revenue Correlation: 99.07 | Revenue CAGR: 68.48% | SUE: 1.17 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.14 | Chg30d=-0.009 | Revisions Net=-4 | Analysts=9
EPS next Year (2026-12-31): EPS=0.63 | Chg30d=-0.031 | Revisions Net=-1 | Growth EPS=+30.9% | Growth Revenue=+17.6%